Who Owns Quince Therapeutics Stock?
NASDAQ: QNCXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 34.49%
- Held by insiders
- 2.90%
- Institutional holders
- 29
- Institutions 34.5%
- Insiders 2.9%
- Public and other 62.6%
Who owns Quince Therapeutics stock?
Institutional investors own about 34.5% of Quince Therapeutics's shares, spread across 29 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 2.90% of QNCX.
The largest institutional holders are Ikarian Capital, LLC (7.39%), Millennium Management Llc (7.24%) and Balyasny Asset Management LP (7.15%). Together, the top 10 institutions control 32.7% of shares outstanding. In their latest filings, 10 of the top 10 institutions increased their QNCX positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of QNCX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Ikarian Capital, LLC | 72.25K | 7.39% | +100.0% |
| Millennium Management Llc | 70.78K | 7.24% | +100.0% |
| Balyasny Asset Management LP | 69.97K | 7.15% | +100.0% |
| Squadron Capital Management LLC | 40.38K | 4.13% | +100.0% |
| Shay Capital LLC | 17.47K | 1.79% | +100.0% |
| Boothbay Fund Management, LLC | 13.91K | 1.42% | +100.0% |
| Jane Street Group, LLC | 12.64K | 1.29% | +100.0% |
| Vanguard Capital Management LLC | 12.04K | 1.23% | +100.0% |
| Cormorant Asset Management, LP | 5.50K | 0.56% | +100.0% |
| UBS Group AG | 4.73K | 0.48% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of QNCX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 12.04K | 1.23% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 4.34K | 0.44% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 2.51K | 0.26% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 580 | 0.06% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 427 | 0.04% |
| Guggenheim Active Allocation Fund | 1 | 0.00% |
Frequently asked questions
Who is the largest shareholder of Quince Therapeutics?
Ikarian Capital, LLC is the largest institutional shareholder of QNCX, owning 7.39% of shares outstanding (72.25K shares) as of its latest 13F filing.
What percentage of Quince Therapeutics is owned by institutions?
Institutions own about 34.5% of QNCX shares and 35.5% of the public float.
How much of Quince Therapeutics do insiders own?
Insiders, such as officers and directors, own about 2.90% of QNCX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.